It's time to rethink how we define effective care." In the same press release, the companys other co-founder and co-CEO Laust Wilster Axelsen added, GLP-1s have created a wave of opportunity, but also a wave of confusion, especially in markets like the U.S
Muscle loss during rapid weight loss is one of the biggest concerns of GLP-1 use, and its one of the reasons women feel weaker, more fatigued, or notice their weight returning if they stop the medication
The long-acting GLP-1 receptor agonists segment is also expected to be the fastest-growing during forecast period, supported by strong demand, clinical success, and ongoing development of next-generation formulations, including oral versions
For instance, TB-500 sulfoxide, which is produced by monocytes when exposed to glucocorticoids, has been shown to inhibit neutrophil chemotaxis and possess strong anti-inflammatory properties [8]